Fig. 2: Engineered myeloid-derived antigen-presenting cells for the induction of tolerance to isogenic/self, autoreactive, or donor antigens.
From: Harnessing bioengineered myeloid progenitors for precision immunotherapies
Myeloid APC derived from a cell donor or differentiated from hiPSC could be primed towards tolerance induction and loaded with autoreactive antigens to reduce autoimmunity (magenta). When organ and APC are derived from the same donor or differentiated from the same HLA-haplotyped hiPSC line, the APC could confer self-tolerance to the transplanted or other cell therapy product (yellow).
